PMV Pharmaceuticals, Inc. (PMVP)

1,7500 +0,0400 (+2,34%) Alla chiusura: 04:00PM EDT

PMV Pharmaceuticals, Inc.

1 Research Way
Princeton, NJ 08540
United States
609 642 6670
https://www.pmvpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 63

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. David H. Mack Ph.D.	Co-Founder, CEO, President & Director	881,08k	N/D	1962
Dr. Arnold J. Levine Ph.D.	Co-Founder, Director & Member of Scientific Advisory Board	140k	N/D	1940
Dr. Deepika Jalota Pharm.D.	Chief Development Officer	593,9k	N/D	1977
Dr. Thomas E. Shenk Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/D	N/D	1947
Mr. Michael Carulli	Chief Financial Officer	N/D	N/D	1974
Mr. Robert Ticktin	General Counsel, Head of Operations & Company Secretary	N/D	N/D	1962
Mr. Tim Smith	Senior VP & Head of Corporate Development and Investor Relations	N/D	N/D	N/D
Ms. Crystal Zuckerman	Vice President of Human Resources	N/D	N/D	N/D
Dr. Binh Vu Ph.D.	Senior VP of Drug Discovery & CMC	N/D	N/D	N/D
Dr. Marc Fellous M.D.	Senior VP and Head of Clinical Development & Medical Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di PMV Pharmaceuticals, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 6; diritti degli azionisti: 7; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.